| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | VIVUS INC | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
Pancreaze is owned by Vivus Inc.
Pancreaze contains Pancrelipase (Amylase;Lipase;Protease).
Pancreaze has a total of 5 drug patents out of which 0 drug patents have expired.
Pancreaze was authorised for market use on 07 March, 2014.
Pancreaze is available in capsule, delayed release;oral dosage forms.
Pancreaze can be used as treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Drug patent challenges can be filed against Pancreaze from 12 April, 2014.
The generics of Pancreaze are possible to be released after 20 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2015 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 12 April, 2014
Market Authorisation Date: 07 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
PANCREAZE family patents
